{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Complete response rate to be defined as an objective status of CR at any time, where confirmation of the complete response status is required on two consecutive evaluations with a second immunofixation before calling the patient a CR. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Categorized by Response Assessment Criteria as specified in Appendix III of the protocol.","groups":[{"description":"Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Ibrutinib: Given PO\n\n\\>\n\n\\> Ixazomib Citrate: Given PO\n\n\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\n\n\\>\n\n\\> Pharmacodynamic Study: Correlative studies\n\n\\>\n\n\\> Pharmacokinetic Study: Correlative studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Ibrutinib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 years","title":"Complete Response Rate (CR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}